As per the report published by Fior Markets, The Global Lungs in Vitro Market is expected to grow from USD 236.62 Million in 2019 to USD 789.76 Million by 2027, at a CAGR of 16.26% during the forecast period 2020-2027. Human lungs are subtle organs and are the main doorway for entry and exit of aerosolized materials and gases. So, have the knowledge about the interaction of aerosolized materials with the lung cells is of great interest in the field of human health. Animal testing is quiet the most prevalent model always used to study various diseases, about new drug development, and for risk assessment. However, in order to decrease animal experimentation, a requirement has arisen for realistic and well-accepted in vitro alternatives. In vitro lung model can be established by culturing macrophages, epithelial cells, and dendritic cells favorable for culture medium. It has been demonstrated that the developed in vitro lung model mimics like lung tissue, in terms of physiology and functionality, in vivo and the cell-cell interactions in this system permit a predictive in vitro screening.
The key factors driving the growth of this market include increasing focus on developing alternatives for animal testing models, advancements in cell culture technologies, and the technological development of new 3D in vitro models. Furthermore, significant rise in research funding and venture capital investments and growing incidence of preventable chronic diseases is boosting the market growth. However, lack of skilled professionals and unfavorable payment models.
The market has been segmented on the basic of type, application and region. Type segment includes 2D cell models and 3D cell models. The 3D cell models segment held largest market share of 55.17% and valued at USD 130.54 million in 2019 due to increasing popularity of the 3D cell models. Application segment includes drug screening, toxicology, 3D model development, basic research, physiologic research, stem cell research, and regenerative medicine. Drug screening held the largest market share of 21.30% and valued at USD 50.40 million in 2019 owing to increasing adoption of the lung in vitro in drug screening applications. The market has been divided into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America held the largest market share of 36.47% and valued at USD 86.30 million in 2019. North America region is driven by the flourishing research environment and abundant funding program such as increased funds for the National Institutes of Health (NIH) and increased R&D activities by biotechnology and pharmaceutical companies.
The market for global lungs in virto market is segmented into key players. Major Player includes ATCC, Lonza, Epithelix, Mattek, Emulate, Mimetas, Tissuse, Insphero, Cn Bio, and among. ATCC held the largest market share of 31.5% in 2019.